Adopting Patient Reported Outcomes in Heart Failure Management
Published: 21 March 2023
-
Views:
9991
-
Likes:
7
-
Views:
9991
-
Likes:
7
-
7m 18sPart 2 Clinical Evidence
-
5m 25s
Overview
This video series is dedicated to the adoption of patient-reported outcomes (PROs) and initiation of guideline-directed medical therapy (GDMT) in daily practice.
In this third and final discussion of the series, Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) and Dr Shelley Zieroth (St Boniface Hospital, Winnipeg, CA) discuss the adoption of patient reported outcomes in clinical management of patients with HF.
Split into three short videos, Dr Kosiborod and Dr Zieroth start by discussing quality of life (QoL) measures and close by looking at the practical implementation of tools, such as the Kansas City Cardiomyopathy Questionnaire (KCCQ), in clinical practice and HF management.
The full series of videos entitled 'Incorporating GDMT and PRO Endpoints for Personalised Heart Failure Management' is available to watch, or you can take the course to earn 1 CME credit.
Key Learning Objectives
- Recall the elements of the Kansas City Cardiomyopathy Questionnaire
- Describe the clinical studies that support the use of functional and QoL measures in practice
- Initiate QoL and functional improvement measures in routine practice
Target Audience
- Cardiologists
- Heart Failure Specialists
- Primary Care Physicians
- Nurses
- Pharmacists
- Other allied HCPs
More from this programme
Part 1
QoL and Functional Measures of Treatment Success
In this opening video, Dr Kosiborod and Dr Zieroth discuss QoL and functional status as tangible measurements of treatment success.
Part 2
Clinical Evidence
Dr Kosiborod and Dr Zieroth look at the relationship between initiating GDMT and QoL / functional status improvement. They discuss some of the specific clinical trial data showing how initiating SGLT-2 inhibitors improves QoL and functional outcomes.
| 1 session | |
| Clinical Evidence | Watch now |
Part 3
Practically Implementing PROMs
In this final part, Dr Kosiborod and Dr Zieroth discuss the practical implementation of these patient reported outcome measures.
| 1 session | |
| Practically Implementing PROMs | Watch now |
About the episode
In this opening video, Dr Kosiborod and Dr Zieroth discuss QoL and functional status as tangible measurements of treatment success.
Faculty Biographies
Mikhail Kosiborod
Cardiologist
Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.
He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.
Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.
Shelley Zieroth
Director, Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.